EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Management Patterns of Teduglutide Use in Short Bowel Syndrome: A Survey of 70 Healthcare Professionals

Felix Harpain iD, Slobodan Milicevic, Lucy Howard iD, Patricia Biedermann iD, Ulrich-Frank Pape iD

Nutrients · 2024

DOI: 10.3390/nu16213762 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nutrients, 2024. Verfasst von Felix Harpain und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Division of Visceral Surgery, Medical University of Vienna, 1090 Vienna, Austria. Hauptthemen laut MEDLINE: Short Bowel Syndrome, Peptides, Gastrointestinal Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Pharmaceuticals International AG., Takeda Pharmaceuticals International AG.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This study aimed to gain real-world insights from healthcare professionals (HCPs) regarding the management of adult patients with short bowel syndrome and intestinal failure (SBS-IF) who received teduglutide and achieved parenteral support (PS) independence or PS volume stability for ≥12 months.

Methods

This cross-sectional survey was conducted in five European countries and Canada via a self-reported questionnaire (November 2022–March 2023) among HCPs who manage patients with SBS-IF and who had prescribed teduglutide to ≥5 patients with SBS-IF receiving PS.

Results

Of the 70 HCPs who completed the survey, almost all reported managing patients with SBS-IF who achieved PS independence or PS volume stability (99%, 69/70 and 97%, 68/70, respectively) and maintained the standard teduglutide dose, without changes. A total of 52 HCPs managed patients who achieved PS independence and discontinued teduglutide. Of these HCPs, 73% (38/52) anticipated that these patients would remain PS-independent, not requiring PS reintroduction. Of the remainder, 79% (11/14) estimated that ≤40% of these patients would require PS reintroduction. While many HCPs (81%, 42/52) would reintroduce teduglutide in patients who discontinued its use after achieving PS independence, none would do so for patients who discontinued teduglutide after achieving PS volume stability if a patient’s condition worsened.

Conclusions

This survey found that patients with SBS-IF can achieve PS independence or PS volume stability with teduglutide treatment. However, some HCPs (27%, 14/52) believe that a proportion of patients discontinuing teduglutide after achieving PS independence will require PS reintroduction. This survey suggests that teduglutide treatment should continue uninterrupted, unless clinically indicated, but this requires confirmation in future studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Short Bowel SyndromePeptidesGastrointestinal AgentsHumansCross-Sectional StudiesSurveys and QuestionnairesMaleFemaleHealth PersonnelAdultCanadaParenteral NutritionEuropeMiddle AgedPractice Patterns, Physicians'

Stichwörter der Autor:innen

intestinal failureparenteral nutritionshort bowel syndromesurveyteduglutide

Substanzen

teduglutidePeptidesGastrointestinal Agents

Autor:innen und Institutionen

  • Department of General Surgery, Division of Visceral Surgery, Medical University of Vienna, 1090 Vienna, Austria.
  • Takeda Pharmaceuticals International AG, 8152 Glattpark, Switzerland.
  • Adelphi Real World, Bollington SK10 5JB, UK.
  • Department of Hepatology and Gastroenterology, Campus Charité Mitte and Campus Virchow-Klinikum, Charité Universitätsmedizin Berlin, 13353 Berlin, Germany.
  • Department of Internal Medicine and Gastroenterology, Asklepios Klinik St. Georg, Asklepios Medical School, 20099 Hamburg, Germany.

ORCID-Profile: Felix Harpain, Lucy Howard, Patricia Biedermann, Ulrich-Frank Pape

Förderung

  • Takeda Pharmaceuticals International AG.
  • Takeda Pharmaceuticals International AG

Zitieren

APA

Harpain, F., Milicevic, S., Howard, L., Biedermann, P., & Pape, U. F. (2024). Management Patterns of Teduglutide Use in Short Bowel Syndrome: A Survey of 70 Healthcare Professionals. Nutrients. https://doi.org/10.3390/nu16213762

Vancouver

Harpain F, Milicevic S, Howard L, Biedermann P, Pape UF. Management Patterns of Teduglutide Use in Short Bowel Syndrome: A Survey of 70 Healthcare Professionals. Nutrients. 2024. doi:10.3390/nu16213762

BibTeX
@article{Harpain2024,
  author = {Harpain, Felix and Milicevic, Slobodan and Howard, Lucy and Biedermann, Patricia and Pape, Ulrich-Frank},
  title = {Management Patterns of Teduglutide Use in Short Bowel Syndrome: A Survey of 70 Healthcare Professionals},
  journal = {Nutrients},
  year = {2024},
  doi = {10.3390/nu16213762}
}
Kostenlos starten →